LGVN Longeveron
- 1.300
- -0.155-10.65%
- 1.310
- +0.010+0.77%
Longeveron News
Longeveron Board Reshuffle and Nasdaq Compliance Efforts
Longeveron Announces Board Transitions
Longeveron: Jeffrey Pfeffer and Cathy Ross Have Voluntarily Resigned From Bd >LGVN
Longeveron: Jeffrey Pfeffer and Cathy Ross Have Voluntarily Resigned From Bd >LGVN
Longeveron Appoints Former Merck Exec Richard Kender to Board >LGVN
Longeveron Appoints Former Merck Exec Richard Kender to Board >LGVN
Longeveron Granted U.S. Patent #11975068: Mesenchymal Stem Cells as Vaccine Adjuvants and Methods for Using the Same
Longeveron Granted U.S. Patent #11975068: Mesenchymal Stem Cells as Vaccine Adjuvants and Methods for Using the Same
Longeverion Granted Israeli Patent Titled 'METHODS OF USING HUMAN MESENCHYMAL STEM CELLS TO EFFECT CELLULAR AND HUMORAL IMMUNITY'
Longeverion Granted Israeli Patent Titled 'METHODS OF USING HUMAN MESENCHYMAL STEM CELLS TO EFFECT CELLULAR AND HUMORAL IMMUNITY'
Longeveron to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
MIAMI, May 02, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing regenerative medicines, today announced that it will report first quarter 2024 financial results
Longeveron Files Prospectus for Secondary Offering
Longeveron (LGVN) on Tuesday filed a preliminary prospectus for resale of about five million class A common shares by selling stockholders. The company said it will not get any of the proceeds from th
Longeveron Is Maintained at Buy by HC Wainwright & Co.
Longeveron Is Maintained at Buy by HC Wainwright & Co.
HC Wainwright & Co. : The Longeveron (LGVN.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $6.00 to $12.00.
HC Wainwright & Co. : The Longeveron (LGVN.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $6.00 to $12.00.
HC Wainwright & Co. Maintains Buy on Longeveron, Adjusts Price Target To $12
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Longeveron (NASDAQ:LGVN) with a Buy, adjusts target to $12 from $6.
Longeveron Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/29/2024 574.16% HC Wainwright & Co. $6 → $12 Maintains Buy 12/04/2023 237.08% HC Wainwright & Co. → $6
Analysts' Top Healthcare Picks: Longeveron (LGVN), Optinose (OPTN)
Longeveron to Present at the Planet MicroCap Showcase
Longeveron Bolsters Market Position With Strategic Financing
Longeveron Raises A Total Of $11.4M In Gross Proceeds From Warrant Exercise Offering And Public Offering
Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or the "Company"), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hy
Peering Into Longeveron's Recent Short Interest
Longeveron's (NYSE:LGVN) short percent of float has fallen 83.09% since its last report. The company recently reported that it has 28 thousand shares sold short, which is 2.79% of all regular shares t
Why Travelers Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of The Travelers Companies, Inc. (NYSE:TRV) fell sharply during Wednesday's session following first-quarter earnings. Travelers reported a mixed first quarter, with earnings lagging analyst' e
Nasdaq Down Over 1%; Sage Therapeutics Shares Plunge
U.S. stocks traded lower midway through trading, with the Dow Jones index falling around 100 points on Wednesday. The Dow traded down 0.32% to 37,678.27 while the NASDAQ fell 1.16% to 15,681.95. The S
Longeveron Shares Drop 31% After Exercise of Warrants
By Chris Wack Longeveron shares were down 25% to $2.65 after the company exercised certain existing warrants to buy 2.4 million shares at an exercise price of $2.35 a share The biotechnology company
Analysis
Price Target
No Data
